📊 BEATW Key Takeaways
Is HeartBeam, Inc. (BEATW) a Good Investment?
HeartBeam is a pre-revenue or early-stage medical device company with severe financial distress, burning approximately $14-21M annually with minimal cash generation. The company's negative profitability metrics (-807% ROE, -360% ROA), combined with unsustainable cash burn rate relative to $4.4M cash reserves, presents existential viability concerns without immediate revenue inflection or capital raise.
HeartBeam appears to be a pre-revenue medical device company with no demonstrated commercial scale, persistent operating losses, and deeply negative returns on equity and assets. While the balance sheet shows no long-term debt and a modest cash cushion, cash burn materially exceeds the current equity base, making future financing risk and dilution pressure central to the story until revenue generation improves.
Why Buy HeartBeam, Inc. Stock? BEATW Key Strengths
- Maintains adequate short-term liquidity with 1.90x current ratio and $4.4M cash position
- Zero long-term debt eliminates near-term refinancing risk and provides capital structure flexibility
- Medical device sector (surgical instruments) operates in growing market with recurring revenue potential if commercialization succeeds
- Debt-free balance sheet with 0.00x debt-to-equity reduces solvency pressure
- Cash of $4.38M covers a meaningful share of near-term obligations and supports a 1.90x current ratio
- Net loss and diluted EPS showed year-over-year improvement, indicating some cost-control progress
BEATW Stock Risks: HeartBeam, Inc. Investment Risks
- No revenue generation with approximately 6-months cash runway at current burn rate; imminent capital raise or insolvency risk
- Severe and deteriorating unit economics with -$21M net loss and -$14M operating cash flow indicating fundamental business model failure
- Minimal balance sheet ($5.8M assets) provides no cushion for development delays or clinical setbacks; high dilution risk for existing shareholders from necessary equity financing
- No reported revenue or gross profit means the business model still lacks proven commercial traction
- Free cash flow of -$14.59M and operating cash flow of -$13.99M imply a short cash runway relative to cash on hand
- Extremely negative ROE and ROA indicate weak capital efficiency and raise the likelihood of additional external funding
Key Metrics to Watch
- Revenue initiation and gross margin sustainability upon commercialization
- Cash burn rate trend and runway to profitability timeline
- Shareholder dilution from capital raises and cumulative losses impact on equity base
- Quarterly revenue commercialization progress and gross margin emergence
- Cash burn trajectory versus cash balance, including financing needs and dilution risk
HeartBeam, Inc. (BEATW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
HeartBeam, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
BEATW Profit Margin, ROE & Profitability Analysis
BEATW vs Healthcare Sector: How HeartBeam, Inc. Compares
How HeartBeam, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is HeartBeam, Inc. Stock Overvalued? BEATW Valuation Analysis 2026
Based on fundamental analysis, HeartBeam, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
HeartBeam, Inc. Balance Sheet: BEATW Debt, Cash & Liquidity
BEATW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: HeartBeam, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.73 indicates the company is currently unprofitable.
BEATW Revenue Growth, EPS Growth & YoY Performance
HeartBeam, Inc. Dividends, Buybacks & Capital Allocation
BEATW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for HeartBeam, Inc. (CIK: 0001779372)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BEATW
What is the AI rating for BEATW?
HeartBeam, Inc. (BEATW) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BEATW's key strengths?
Claude: Maintains adequate short-term liquidity with 1.90x current ratio and $4.4M cash position. Zero long-term debt eliminates near-term refinancing risk and provides capital structure flexibility. ChatGPT: Debt-free balance sheet with 0.00x debt-to-equity reduces solvency pressure. Cash of $4.38M covers a meaningful share of near-term obligations and supports a 1.90x current ratio.
What are the risks of investing in BEATW?
Claude: No revenue generation with approximately 6-months cash runway at current burn rate; imminent capital raise or insolvency risk. Severe and deteriorating unit economics with -$21M net loss and -$14M operating cash flow indicating fundamental business model failure. ChatGPT: No reported revenue or gross profit means the business model still lacks proven commercial traction. Free cash flow of -$14.59M and operating cash flow of -$13.99M imply a short cash runway relative to cash on hand.
What is BEATW's revenue and growth?
HeartBeam, Inc. reported revenue of N/A.
Does BEATW pay dividends?
HeartBeam, Inc. does not currently pay dividends.
Where can I find BEATW SEC filings?
Official SEC filings for HeartBeam, Inc. (CIK: 0001779372) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BEATW's EPS?
HeartBeam, Inc. has a diluted EPS of $-0.62.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BEATW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, HeartBeam, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BEATW stock overvalued or undervalued?
Valuation metrics for BEATW: ROE of -807.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BEATW stock in 2026?
Our dual AI analysis gives HeartBeam, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BEATW's free cash flow?
HeartBeam, Inc.'s operating cash flow is $-14.0M, with capital expenditures of $600.0K.
How does BEATW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -807.3% (avg: 15%), current ratio 1.90 (avg: 2).